Jeffrey Wager
Chief Executive Officer at SPEXIS AG
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kuno Sommer | M | 68 | 12 years | |
| Dan Hartman | M | 62 |
EnBiotix, Inc.
 EnBiotix, Inc. Medical/Nursing ServicesHealth Services EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA. | 12 years |
| Dennis Ausiello | M | 78 |
EnBiotix, Inc.
EnBiotix, Inc. Medical/Nursing ServicesHealth Services EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA. | 3 years |
| Stephan Wehselau | M | 55 |
Proterris, Inc.
 Proterris, Inc. Pharmaceuticals: MajorHealth Technology Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA. | 4 years |
| Robert Clarke | M | 56 |
EnBiotix, Inc.
EnBiotix, Inc. Medical/Nursing ServicesHealth Services EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA. | 5 years |
| Bernard Bollag | M | 63 | 11 years | |
| Joseph Wager | M | - |
Proterris, Inc.
Proterris, Inc. Pharmaceuticals: MajorHealth Technology Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA. | - |
| Martin Jakobovic | M | - | - | |
| Matthew Bennett | M | 52 |
Proterris, Inc.
Proterris, Inc. Pharmaceuticals: MajorHealth Technology Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA. | 7 years |
| Juergen Froehlich | M | 68 | 3 years | |
| Peter Hutt | M | 89 |
Proterris, Inc.
Proterris, Inc. Pharmaceuticals: MajorHealth Technology Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA. | 11 years |
| Joseph deBethizy | M | 74 |
Proterris, Inc.
Proterris, Inc. Pharmaceuticals: MajorHealth Technology Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA. | 11 years |
| Mathew Bennett | M | - |
Proterris, Inc.
Proterris, Inc. Pharmaceuticals: MajorHealth Technology Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA. | - |
| Roberto Luis Guttmann | M | 66 |
EnBiotix, Inc.
EnBiotix, Inc. Medical/Nursing ServicesHealth Services EnBiotix, Inc. operates as a late clinical-stage respiratory therapeutics company, which engages in deploying novel systems and synthetic biology technologies. It offers anti-persisters, engineered bacteriophage, tunable target degradation, and systems biology platform. Its pipeline includes ColiFin, EBX-001, EBX-002, and Linear Peptide Antibiotics. The company was founded by James J. Collins in 2012 and is headquartered in Boston, MA. | - |
| Muriel Fleming | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gökhan Batur | M | 42 | 3 years | |
| Daniel Obrecht | M | 69 | 25 years | |
| Hernan Levett | M | 49 | 4 years | |
| Franziska Müller | F | 42 | 13 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 13 | 68.42% |
| United States | 10 | 52.63% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jeffrey Wager
- Personal Network